The purpose of this study is to determine whether there is greater activity for carboplatin
than a taxane standard of care (docetaxel) in women with ER-, PR- and HER2- breast cancer.
The trial aims to recruit between 370 and 450 patients.
Phase:
Phase 3
Details
Lead Sponsor:
Institute of Cancer Research, United Kingdom
Collaborators:
Breakthrough Breast Cancer Cancer Research UK King's College London